Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca

First Page		Document Content
Date: 2015-05-13 10:22:06 Myelofibrosis Janus kinase inhibitor Essential thrombocytosis Thrombocytosis Splenomegaly Polycythemia vera Myeloproliferative disease Thrombocytopenia TG101348 Medicine Hematopathology Ruxolitinib		Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca Add to Reading List Source URL: www.novartis.ca Download Document from Source Website File Size: 177,73 KB Share Document on Facebook

	1 Dr James Vardiman Professor Emeritus Department of Pathology University of Chicago DocID: 1o8ES - View Document
	Molecular Diagnosis of Myeloid Neoplasias and Solid Tumors First report of mutations detected in the gene for NF-E2 Technology Myeloproliferative Neoplasms (MPN) are a group of several distinct, but clinically related ma DocID: 1adts - View Document
	Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard DocID: 19YPO - View Document
	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca DocID: 19fx5 - View Document
	Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre DocID: 19eKj - View Document